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Regulatory Framework
• Primary responsibility for regulation of clinical trials rests
with agencies of the U.S. Department of Health and
Human Services (HHS).
• These are:







Office for Human Research Protections (OHRP)
Office of Civil Rights (OCR)
Food and Drug Administration (FDA)
Office of Research Integrity (ORI)
National Institutes of Health (NIH)
Centers for Medicare and Medicaid Services (CMS)

• Primary regulatory concern is: Protection and well-being
of human subjects.

Regulatory Framework
 Three FDA centers regulate medical investigational products
for human use:
 Center for Drug Evaluation and Research (CDER)
 Center for Biologics Evaluation and Research (CBER)
 Center for Devices and Radiological Health (CDRH)
 FDA’s Office of Regulatory Affairs (ORA) conducts onsite
bioresearch monitoring inspections of sponsors, PIs and IRBs
 Enforcers: OIG/DOJ/FBI/State AGs/Health Care Fraud
Prevention and Enforcement Action Team

Clinical Trial Billing
• Medicare Coverage Policy
• NCD 310.1 states that Medicare will cover “routine costs of
qualifying clinical trials...as well as reasonable and necessary
items and services used to diagnose and treat complications
arising from participation in all clinical trials. All other Medicare
rules apply.” -NCD for Routine Cost in Clinical trials (310.1)

• Many commercial payers follow Medicare
• The NCD clinical trials policy does not address device
studies. Organizations are required to work with their
Medicare Administrative Contractor (MAC) to determine
coverage for device studies.

States That Require Health Plans to
Cover Patient Care Costs in Clinical
Trials

Taken from the National Cancer Institute website, March 2011
http://www.cancer.gov/clinicaltrials/education/laws

CMS Coverage of Medical Devices
• WPS Medical Director review not required for
• Devices approved through FDA pre-market approval process
• Devices cleared through FDA 510(k) process

• WPS Medical Director approval is required for:
• FDA-approved IDE Category B devices
• IRB-approved medical devices

• Devices typically not covered include:
• FDA-approved Category A devices
• EXCEPTION may be granted by CMS / WPS Medical Director
for use in a “life threatening condition.”

Category B IDEs
• FDA-approved IDE Category B devices
• Routine costs associated with these studies are covered if the
study is approved by the local Medicare Medical Director
• If approved, the device can be billed to Medicare if it is not
provided for free by the sponsor or promised free in the informed
consent form
• Medicare coverage is based on the device continuing to meet
criteria that led to the FDA category designation
• Payment is limited to or less than what Medicare would have
paid for a comparable device
• Payment under Medicare for Category B devices will be based
on information provided in the IDE submission and clearly stated
in the IDE exemption letter

Category B IDEs
• FDA-approved IDE Category B devices
• Providers are required to identify claims with the proper
modifiers
• Claims should include the IDE number assigned to the device

CMS Submission Requirements
• Provider name and number (for Part A it would be the
institution name and number, for Part B it would be the PI
provider number along with the mailing address)
• For Part B, all co-investigators that will bill for services must also be
listed with the submission.
• Name and Number of the investigational device(s) utilized in the
trial.
• A narrative description of the device(s).
• Signed copy of the FDA-approval letter demonstrating category A or
B IDE status.

CMS Submission Requirements
• The FDA letter containing the most current approved number
of institutions and subjects (may be 2 separate letters).
• Number of Medicare cases planned for the study at the
specific institution.
• A copy of the final protocol from the sponsor.
• Additional items to be maintained at the site and readily
available
– The agreement between the company or manufacturer and the
provider, furnishing the details of the provider participation.
– At least 2 peer-review publications.
– Any product literature illustrating the device and/or procedure.
– IRB-approval for the protocol to be carried out at the institution.

BJC/ WUSM Approval Process
Step 1: Notification of Device Trial
•

•

WUSM Contracts Department notifies BJH Research Billing Compliance
and the WU Clinical Research Billing Support office via e-mail of any new
device trial as it comes to that office. Documents available at that time are
attached.
Clinical Research Billing Support-Secretary (Jan Light) notifies BJH
Research Compliance (Darlene Szczuka) via e-mail when she receives an
IRB application for a new device trial and forwards the HRPO approval.
Kelly Granda is copied on this e-mail transmission.

Step 2: Communication with Study Team
•

Upon receiving knowledge of the trial, BJH will send an e-mail to the study
coordinator informing them that she will be gathering the required
documents and will send one packet including those documents and the
request for coverage letter from both institutions. She will request the letter
from the physician (or representative) be sent to her for mailing.

BJC/ WUSM Approval Process
Step 3: Gathering Documents
•

BJH acquires required documents from CCS contracts, CCS Clinical
Research Billing Support, department coordinators, and sponsors as
appropriate.

Step 4: Sending the packet to WPS
•

Upon receipt of all necessary documents and letters, BJH will write a cover
letter to Dr. Stephen Boren (CMS) informing him that the packet includes
requests from both entities. This letter is scanned and e-mailed to the
coordinator listed on the device form along with the following individuals:
the coordinator, the PI, Denise McCartney, Melanie Rowe, Deb Wierciak,
William Woloszyn, and if the trial is within the Department of Surgery, Kathy
Hoertel .

BJC/ WUSM Approval Process
Step 5: Review Process issues
•

Any requests or questions coming from WPS will be directed to the
appropriate entity.

Step 6: WPS Approval letter receipt
•

BJH will inform the coordinator when approval is granted and will request
that WU reciprocate and send the WU approval letter to her.

Quick Summary
• Device Trial Coverage: Medicare requires the MAC
Medical Director’s approval
– Category A IDE: when studying a life-threatening condition
– Category B IDE: when Medicare contractor approves coverage
– PMA: generally covered with approval (if MAC requests)
• Note: Carotid artery stent PMAs must be submitted

– Labeled Use: generally covered with approval (if MAC requests)

Questions
For More Information Contact:
Carlos Brown @ 362-0938
or
Yi Zhang @ 362-6864

